<DOC>
	<DOCNO>NCT00046371</DOCNO>
	<brief_summary>The purpose study examine immunological response rate administration THERATOPE® vaccine woman stable metastatic breast cancer treat aromatase inhibitor Faslodex® require chemotherapy . Post-menopausal woman aromatase inhibitor Faslodex® alone pre-menopausal woman aromatase inhibitor plus luteinising hormone-releasing hormone ( LH/RH ) -agonist may eligible enrolled . Patients must radiotherapy major surgery within four ( 4 ) week prior enter study . Information safety tolerability administration THERATOPE® vaccine also gather course study .</brief_summary>
	<brief_title>Safety Immunological Response Rate Study THERATOPE® Vaccine Metastatic Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria Histopathologically confirm breast cancer Documented Stage IV disease Estrogen and/or progesteronereceptor positive Stable disease aromatase inhibitor Faslodex® treatment begin least 12 week prior enrolment Performance status , ECOG = 0 1 Life expectancy &gt; 12 week History freedom progression least 6 month follow surgery curative intent least 6 month adjuvant chemotherapy , adjuvant radiotherapy adjuvant hormonal therapy tamoxifen/toremifene treatment No radiotherapy major surgery within 4 week prior enrolment Exclusion Criteria Pregnant lactate Known brain metastasis Bone marrow involvement site metastasis First line chemotherapy Stage IV disease Past current cancer breast cancer , except curatively treat basal cell cancer situ cancer cervix evidence disease Autoimmune disease , e. g. , type I juvenile onset diabetes mellitus , antibody positive rheumatoid arthritis , Grave 's disease , lupus , Crohn 's disease , IBD , Hashimoto 's thyroiditis Known intercurrent infection ( include HBV HCV ) immunosuppression [ human immunodeficiency virus ( HIV ) condition ] clinical evidence condition Other significant active infection Pleural effusion and/or ascites require paracentesis every 2 week frequently Splenectomy Concurrent treatment chemotherapeutic agent lowdose cyclophosphamide use study Treatment interferon ( IFNs ) , cytokine , systemic steroid biologicals within 4 week prior enrolment Receipt another investigational drug within 30 day enrolment Known allergy shellfish Known allergy soy bean soy product Known hypersensitivity polysorbate 80 Known hypersensitivity study drug Legal incapacity limit legal capacity</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>Cancer Vaccines</keyword>
	<keyword>Aromatase</keyword>
	<keyword>Receptors , Estrogen</keyword>
	<keyword>Receptors , Progesterone</keyword>
</DOC>